For these reasons, VDAC1 has rapidly emerged as a putative pharmacological target in the treatment of various pathologies, including AD in which the mitochondrial dysfunction is partially attributable to the toxic interaction of intracellular Aβ oligomers with the porin. This evidence concerns the gene VDAC1 and Alzheimer disease.